pharmaceutical manufacture

Janvier 30, 2017 4:46PM

Canada’s inadequate intellectual property rights protections hurt patients and the economy

There are numerous deficiencies that weaken intellectual property protections within Canada relative to other industrialized countries.

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Janvier 24, 2017 1:00AM

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Kristina M.L. Acri, née Lybecker

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Octobre 14, 2016 1:30AM

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Steven Globerman, Kristina M.L. Acri, née Lybecker, Christopher Sands, Tomas J. Philipson

Étiquettes:

intellectual property rights, intellectual property for pharmaceuticals, intellectual property protection, pharmaceutical innovation, biologics, pharmaceutical manufacture

Mai 6, 2003 2:00AM

Drug Disincentives

John R. Graham

In January, GlaxoSmithKline, a global pharmaceutical manufacturer, announced that it would stop delivering its prescription drugs to wholesalers that supply Canadian mail order pharmacies that sell to American patients. These pharmacies, clustered in Manitoba, take advantage of the price difference between the two countries. Recently, AstraZeneca, an Anglo-Swedish pharmaceutical manufacturer, indicated that it would take similar action. Glaxo has weathered a storm of accusations that it is preventing American patients from getting the companys medicines at affordable prices.

Étiquettes:

prescription drugs, mail order pharmacies, cross-border pharmacies, GlaxoSmithKline, pharmaceutical manufacture, drug prices, canadian drug prices, american drug prices

Formulaire de recherche

pharmaceutical manufacture

Canada’s inadequate intellectual property rights protections hurt patients and the economy

Intellectual Property Rights Protection and the Biopharmaceutical Industry: How Canada Measures Up

Intellectual Property Rights and the Promotion of Biologics, Medical Devices, and Trade in Pharmaceuticals

Drug Disincentives